{"title":"Safety and Efficacy of Ponatinib for Pulmonary Tumor Thrombotic Microangiopathy.","authors":"Kimi Sato, Naoto Kawamatsu, Masayoshi Yamamoto, Tomoko Machino-Ohtsuka, Tatsuhiro Sakamoto, Takeshi Yamada, Yoshiyuki Yamamoto, Masato Homma, Bryan J Mathis, Ikuo Sekine, Tomoko Ishizu","doi":"10.1253/circrep.CR-26-0218","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>We evaluated the safety and efficacy of ponatinib, a multi-target tyrosine kinase inhibitor, for pulmonary tumor thrombotic microangiopathy (PTTM).</p><p><strong>Methods and results: </strong>We conducted a single-center, open-label, single-arm, prospective study; 3 patients associated with ovarian, breast, and gastric carcinomas were enrolled and received oral ponatinib for 2 weeks. All died from PTTM progression with no severe ponatinib-related adverse events.</p><p><strong>Conclusions: </strong>This study failed to demonstrate ponatinib efficacy. Further studies may evaluate the effect of different biochemical targets on PTTM.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"8 10","pages":"1758-1760"},"PeriodicalIF":2.3000,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13649527/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Circulation reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1253/circrep.CR-26-0218","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/10/9 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: We evaluated the safety and efficacy of ponatinib, a multi-target tyrosine kinase inhibitor, for pulmonary tumor thrombotic microangiopathy (PTTM).
Methods and results: We conducted a single-center, open-label, single-arm, prospective study; 3 patients associated with ovarian, breast, and gastric carcinomas were enrolled and received oral ponatinib for 2 weeks. All died from PTTM progression with no severe ponatinib-related adverse events.
Conclusions: This study failed to demonstrate ponatinib efficacy. Further studies may evaluate the effect of different biochemical targets on PTTM.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
